

Electronic Acknowledgement Receipt

| | |
|---|---|
| EFS ID: | 4106560 |
| Application Number: | 10589450 |
| International Application Number: | |
| Confirmation Number: | 5684 |
| Title of Invention: | Anti-EpCam Immunoglobulins |
| First Named Inventor/Applicant Name: | Malte Peters |
| Customer Number: | 32425 |
| Filer: | Steven Lee Highlander/Christopher Jackson |
| Filer Authorized By: | Steven Lee Highlander |
| Attorney Docket Number: | DEBE:069US/10612950 |
| Receipt Date: | 14-OCT-2008 |
| Filing Date: | 04-MAY-2007 |
| Time Stamp: | 10:50:18 |
| Application Type: | U.S. National Stage under 35 USC 371 |

Payment information:

| | |
|---|----------------------|
| Submitted with Payment | yes |
| Payment Type | Credit Card |
| Payment was successfully received in RAM | \$130 |
| RAM confirmation Number | 11942 |
| Deposit Account | 501212 |
| Authorized User | HIGHLANDER,STEVEN L. |
| The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: | |
| Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees) | |
| Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees) | |

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

| Document Number | Document Description | File Name | File Size(Bytes)/ Message Digest | Multi Part /.zip | Pages (if appl.) |
|-----------------|--|------------------|--|------------------|------------------|
| 1 | Response to Election / Restriction Filed | DEBE069US_RR.pdf | 48502 af508c58eca7adfeef9d985c68f511620bf9910 | no | 2 |

Warnings:

Information:

| | | | | | |
|---|-------------------|-------------------|--|----|---|
| 2 | Extension of Time | DEBE069US_EOT.pdf | 61310 1381d4b1fc8b594a9454b935b78abfb23d88ads | no | 1 |
|---|-------------------|-------------------|--|----|---|

Warnings:

Information:

| | | | | | |
|---|------------------------|--------------|--|----|---|
| 3 | Fee Worksheet (PTO-06) | fee-info.pdf | 30439 0a54e58a3607a59800160913ec2610d20113559 | no | 2 |
|---|------------------------|--------------|--|----|---|

Warnings:

Information:

Total Files Size (in bytes): 140251

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.